Product Description
Tirzepatide is a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a single molecule engineered to activate two incretin pathways simultaneously. The GLP-1 component delivers appetite suppression and gastric motility effects; the GIP component adds a parallel metabolic route via adipocyte-receptor activation, improving insulin sensitivity and fatty-acid metabolism independent of GLP-1 signaling.









